SAGE Therapeutics (SAGE), MGH Announce Publication of Epidemiology of SRSE Data
- Apple (AAPL) Tops Q4 EPS by 2c; Issues Solid Outlook
- Wall Street slips on earnings; Apple falls late after results
- Chipotle Mexican Grill (CMG) Posts Q3 EPS of $0.27; Comps Miss Views; Additional Stock Buyback Approved
- Pandora (P) Misses Q3 EPS by 1c, Q4 Revenue Guidance Falls Short
- After-Hours Movers 10/25: (OGXI) (AKAM) (VRTX) Higher; (EW) (NUVA) (CMG) (AAPL) Lower (more...)
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Sage Therapeutics (Nasdaq: SAGE) announced the publication of a study conducted with collaborators from Massachusetts General Hospital (MGH) on the epidemiology of super-refractory status epilepticus (SRSE). The paper, titled “Burden of illness for super-refractory status epilepticus,” was recently published in the Journal of Medical Economics (doi: 10.1080/13696998.2016.1223680).
“While SRSE has been known to be a devastating, life-threatening condition associated with high cost of care, few studies have examined the incidence rate or quantified the healthcare resource utilization of this condition,” said Lidia Moura, MD, MPH, a neurologist and health services researcher in the Department of Neurology at MGH and Harvard Medical School and co-author of the paper. “In addition, most of the existing studies focused on smaller patient populations outside of the U.S. The findings from this study help to provide a new understanding of the high mortality and morbidity, and significant use of healthcare resources associated with SRSE.”
“This research, undertaken by Sage and our collaborators, helps to provide a new data-driven understanding of the clinical and economic costs of SRSE,” said Tom Anderson, Chief Commercial Strategy Officer of Sage. “By estimating the potential patient population and related medical expenses associated with SRSE, the data highlight the tremendous need for development of treatment options for this disorder and the importance of conducting additional studies in SRSE.”
Study Summary and Key Findings:
- The Premiere Hospital Database was utilized to estimate the annual number of SRSE cases in the U.S. and to evaluate utilization of hospital resources by SRSE patients based on hospital discharges during 2012. The Premiere Hospital Database included 5.3 million hospital discharges in 2012, accounting for approximately 20% of U.S. annual hospital discharges.
- SRSE does not currently have a specific ICD-9 (International Classification of Diseases, 9th Revision) code and status epilepticus codes are used inconsistently. Discharges were classified as SRSE cases in the study based on an algorithm using seizure-related International Classification of Diseases-9 (ICD-9) codes, Intensive Care Unit (ICU) length of stay (LOS) and treatment protocols (e.g., benzodiazepines, antiepileptic drugs and ventilator use). Secondary analyses were conducted using more restrictive algorithms for SRSE.
- A total of 6,325 hospital discharges were classified as SRSE cases using the primary algorithm from the total 5.3 million hospital discharges in 2012 in the Premiere Hospital Database. This projects to an estimated 41,156 cases of SRSE in the U.S. during 2012, or an estimated annual incidence rate of approximately 13/100,000, when applying a weighted projection based on hospital characteristics and 2012 U.S. demographics. Secondary analyses using stricter algorithms to classify SRSE resulted in an estimated 35,150 annual SRSE cases (or an incidence rate of approximately 11/100,000) and 25,915 annual SRSE cases (or an incidence of 8/100,000), respectively. Given the limitations of the methodology, the authors noted that more in-depth studies are needed.
- The mean LOS for SRSE hospitalizations was 16.5 days and the mean LOS in the ICU was 9.3 days. The most common LOS was 10-19 days. Twenty-four percent of SRSE patients spent 20 or more days in the hospital. The mean cost of an SRSE hospitalization was $51,247, increasing with LOS to a mean cost of $156,500 for patients with LOS of 30 or more days (11% of SRSE cases identified).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Federal Signal (FSS) Executive Chairman Dennis J. Martin to Retire
- Vertex Pharma (VRTX) Misses Q3 EPS by 2c; Plans to Commence Two CF-Focused Phase 2s
- Endologix (ELGX) Names New Chief Medical Officer
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!